Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 15/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8672820 | 0.85 | LTA4H (0.74) | LTA4HL3MBTL1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6474449 | 0.84 | LMNA (0.62) | LTA4HL3MBTL1CYP1A2CYP2C19LMNA | |
| SCHEMBL2091073 | 0.83 | LTA4H (0.60) | LTA4HL3MBTL1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL53853 | 0.83 | KCNA3 (0.67) | LTA4H | |
| SCHEMBL8773767 | 0.80 | LTA4H (0.59) | LTA4HL3MBTL1 | |
| SCHEMBL14356072 | 0.80 | ALDH1A1 (0.69) | LTA4HL3MBTL1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9162686 | 0.80 | LTA4H (0.67) | LTA4HL3MBTL1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3039068 | 0.80 | LTA4H (0.67) | LTA4HL3MBTL1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7440978 | 0.80 | L3MBTL1 (0.69) | LTA4HL3MBTL1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3046381 | 0.80 | LTA4H (0.67) | LTA4HL3MBTL1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107468-A1 | Process for the preparation of an enantiomerically enriched thio compound | DSM IP ASSETS B.V. (NL) | 2005-05-19 | — | — | US | disclosed |
| EP-1453797-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND | DSM IP Assets B.V. (NL) | 2004-09-08 | — | — | EP | disclosed |
| EP-1325908-A1 | Process for the preparation of an enantiomerically enriched thio compound | DSM N.V. (NL) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003051827-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND | DSM IP ASSETS B.V. (NL) | 2003-06-26 | — | — | WO | disclosed |
| US-5723492-A | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5719306-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107468-A1 | Process for the preparation of an enantiomerically enriched thio compound | SLC7A1, TCP1, TFRC | LTA4H 1466/4885L3MBTL1 1903/4885CYP1A2 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.